Phase I trial begins using gene therapy and bone marrow stem cells in the treatment of brain cancer
Monday, November 14, 2011 - 12:02
in Health & Medicine
University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting toxicity of chemotherapy with Temodar.